Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 495-498

  Schmider, Jürgen ^a   Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Karsov, Dmitry ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; Cytochrome P 450; Desmethylsertraline; Fluoxetine; Fluvoxamine; Human liver microsomes; In vitro; Metabolism; Norfluoxetine; Paroxetine; Phenytoin; Selective serotonin reuptake inhibitor; Sertraline

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

EID: 0030706197     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00601.x     Document Type: Article

References (32)

1. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-261.
2. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-246.
3. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
4. von Moltke LL, Greenblatt OJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
5. von Moltke LL, Greenblatt DJ, Cotreaw-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
6. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms, and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275: 592-597.
7. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
8. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
9. Jahl P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports [letter]. J Neurol Neurosurg Psychiat 1992; 55: 412-413.
10. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994; 14: 375-376.
11. Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine. N Z Med J 1994; 107: 19.
12. Darley J. Interaction between phenytoin and fluoxetine. Seizure 1994; 3: 151-153.
13. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
14. Tassaneeyakul W, Veronese ME, Birkett DJ, et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992; 34: 494-498.
15. Schmider J, Greenblatt DJ, von Moltke LL, et al. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies. Pharmacology 1996; 52: 125-134.
16. Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. eds.: New York: Wiley & Sons, Inc., 1975: 100-160.
17. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to phamacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16: 104-112.
18. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996; 16: 197-201.
19. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions; implications for diazepam disposition in humans. J Clin Psychopharmacol 1996; 16: 267-272.
20. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other serotonin-reuptake-inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-131.
21. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996; 36: 792-798.
22. Bailey DN, Shaw RF. Interpretation of blood and tissue concentrations in fatal self-ingested overdose involving amitriptyline: an update (1978-1979). J Anal Toxicol 1980; 4: 232-236.
23. Fraser AD, Isner AF, Perry RA. Distribution of trimipramine and its major metabolites in a fatal overdose case. J Anal Toxicol 1987; 11: 168-170.
24. Levine B, Jenkins AJ, Smialek JE. Distribution of sertraline in postmortem cases. J Anal Toxicol 1994; 18: 272-274.
25. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part I). Clin Pharmacokin 1990; 18: 37-60.
26. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiat 1996; 57[suppl 1]: 24-28.
27. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266: 964-971.
28. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Aberg G, Shader RI. Differential inhibition of desipramine hydroxylation in vitro by the enantiomers of fluoxetine. Clin Pharmacol Ther 1995; 37: 205.
29. Fuller RW, Perry KW. Comparison of fluoxetine and norfluoxetine enantiomers as inhibitors of hexobarbitone metabolism in mice. J Pharm Pharmacol 1992; 44: 1041-1042.
30. Hanger HC, Thomas F. Fluoxetine and warfarin interactions. N Z Med J 1995; 108: 157.
31. Woolfrey S, Gammack NS, Dewar MS, Brown PJ. Fluoxetine-warfarin interaction. Br Med J 1993; 307: 241.
32. Physician's Desk Reference, 1996. eds.: Oradell NJ: Medical Economies Co., 1996: 2545.